Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Patient 600 recruited Precision-Panc Enters 500th patient to platform Professor Andrew Biankin – it’s about time Pancreatic Cancer is debated in the Scottish Parliament Please watch this very moving video from NIHR West of England Exciting week for the Precision-Panc project Glasgow to host Pancreatic Symposium – Friday 21st May 2021 Survey on the impact of COVID-19 pandemic on pancreatic cancer research Precision-Panc in the Press Precision-Panc / PRIMUS 002 Opens a new site Precision-Panc Re-opens to Recruitment Information on COVID-19 and Pancreatic Cancer from PCUK Precision-Panc and PRIMUS studies suspended to recruitment Precision-Panc Recruits Patient 300 Paul Taylor tells us about his Precision-Panc experience Precision-Panc help raise funds for Pancreatic Cancer Scotland Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Home | Patients and Carers | What is Pancreatic Cancer?

What is Pancreatic Cancer?

Our bodies are made up of many different kinds of cells that routinely grow and divide in an organised way throughout our lifetime. When these cells multiply and grow in an uncontrolled or abnormal way, then cancer can develop.

Pancreatic cancer occurs when the cells in the pancreas organ begin to grow and form a lump. This growth can interfere with the way that your pancreas functions.

These alterations in cell growth are most commonly caused by changes, called mutations, in the DNA that carries the instructions the cells follow when they grow. Mutations can confuse the cell, which means it does not stop growing when it should. It is not always clear why mutations happen. Some are inherited from your parents and others happen over time while you age. 5-10% of pancreatic cancers are caused by inherited mutations.

What is the pancreas?

What is the pancreas?

The pancreas is a leaf shaped organ in your body that can be found between the stomach and backbone and is part of your digestive system.
It has two important functions:
• producing enzymes which break down food to allow the body to absorb nutrients
• producing a range of hormones including insulin which help keep the level of sugar in your blood at a steady level

There are three main parts of the pancreas which are called the head, body and tail.

The head is the widest part of the organ nearest to the small intestine and is the most common site of pancreatic tumour growth. The body is the middle section and around 15% of cancers are found here. Finally, the tail is the thinnest part of the pancreas. Only 5% of pancreatic tumours are found here.

Types of pancreatic cancer

Not all cells in the pancreas are the same.  They differ depending on the role that they play.
The cells in the pancreas that produce pancreatic enzymes are known as exocrine cells. Exocrine pancreatic tumours are made up of these cells and are the most common type of pancreatic cancer.
9/10 (90%) of exocrine pancreatic cancer is known as pancreatic ductal adenocarcinoma (shortened to PDAC). This particular cancer develops in the channels, known as ducts, which carry pancreatic juice from the pancreas into the small bowel. Other types of exocrine cancers are rare.
The cells that produce hormones are known as endocrine cells. Tumours that grow from these cells are known as endocrine cancers. They account for only 5 in 100 (5%) of all pancreatic cancers. These tumours can also called pancreatic neuroendocrine tumours (PNETS) or islet cell tumours.
Endocrine pancreatic tumours are treated differently to exocrine tumours so it is important to know what kind of pancreatic cancer you have.

Stages of pancreatic cancer

The stage of a cancer reflects the size of the cancer and how far it has spread.
This means knowing the size of the tumour (T), if there are any cancer cells present in the lymph nodes (N) and if the cancer has spread from the pancreas to any other organ in the body (M). This is described as the TNM stage of a cancer and gives a stage from 1-4

Stage 1 – the earliest stage and the cancer is found only in the pancreas.
Stage 2 – the cancer has spread into nearby tissues and/or there is cancer in lymph nodes near the pancreas.
Stage 3 – the cancer has spread into the large blood vessels near the pancreas and/or the stomach, spleen or large intestine.
Stage 4 – the cancer has spread to distant sites such as the liver, lungs or bones.

Risks and Signs of Pancreatic Cancer

Pancreatic cancer is unusual before the age of 40, more commonly in those over 70 years of age.
Risk factors for pancreatic cancer include
• tobacco smoking
• Obesity
• Diabetes
• Chronic pancreatitis (inflammation of the pancreas)
• Hereditary pancreatitis
Signs and symptoms can be similar to common illnesses and are as varied as upper abdominal pain, jaundice (yellowish skin and whites of the eyes), dark urine, loss of appetite, weight loss, bowel problems or blod clots, but these may not appear until pancreatic cancer is quite advanced and surgical removal is not possible.

Current Treatments and Outcomes

Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy or palliative care, or a combination of these.
One reason for the poor outcomes for pancreatic cancer is that it is often diagnosed late. By the time someone has symptoms, goes to their doctor and is diagnosed, the cancer is very often quite advanced. About 15% of patients can have surgery to remove their pancreas, which gives the only chance of cure.
Pancreatic ductal adenocarcinoma typically has a very poor outcome: after diagnosis 20–25% of people survive one year and 5% live for five years. Even in those lucky enough to have surgery, only 25–30% will live for five years. Only 1% will survive their cancer for 10 years or more after diagnosis.
For those whose pancreatic cancer has spread into other parts of the body and surgery is not possible, patients will live about six months to a year.
Gemcitabine was the chemotherapy standard for many years for people with advanced pancreatic cancer. Then from 2007, doctors began to combine Gemcitabine with other drugs that target specific abnormalities within cancer cells, as in the case of Erlotinib (Tarceva) which blocks chemical signals causing cancer cells to multiply. While these combinations, including with Capecitabine, improves the way Gemcitabine works, they have still not significantly changed survival rates.
More recently, the Gemcitabine plus nab-Paclitaxel (Abraxane®) and FOLFIRINOX combinations have become the standard of care for patients who are well enough to cope with the significant side effects. However, these newer treatments only extend survival by a few months at best – the two-year survival rate for advanced disease remains less than 10%.
Importantly, there are small groups of patients who will derive significant benefit from some of these therapies. Identifying these patients before commencing treatment, and not giving treatments to patients when they will not work may seem obvious, but this is the current challenge facing doctors involved in cancer care.
As pancreatic cancer spreads to nearby lymph nodes and other organs, the increasing burden of symptoms means that patients are no longer well enough to have surgery, radiotherapy or chemotherapy and the primary medical focus is on making the patient comfortable.

© 2024 Precision Panc
Web design by Creatomatic
This site uses cookies.
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.